TRAVERE THERAPEUTICS

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Jun 2024 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 May 2024 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

09 May 2024 16:30:56 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

08 May 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2024 Financial Results

06 May 2024 16:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2024 Financial Results

29 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

24 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

04 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

03 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Mar 2024 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

11 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

26 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

23 Feb 2024 07:05:39 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

15 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

08 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

01 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

25 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2024 Outlook

08 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

14 Dec 2023 07:30:00 By Nasdaq GlobeNewswire